BÜHLMANN fCAL® turbo Citation: Nilsen, T. et. al. A novel turbidimetric immunoassay for fecal calprotectin optimized for routine chemistry analyzers. J Clin Lab Anal. 2016 Sep 15. PMID:27629827 The publication describes the technical performance of the turbidimetric assay on the cobas c501 and the Mindray BS-380. Highlight from this Publication Short assay time of 10 min with
Read more
- info@buhlmannlabs.ch
- +41 61 487 12 12
News
More than 50 independent publications have proven the clinical performance and reliability of our fecal calprotectin assays in diagnosis and monitoring of IBD patients. The BÜHLMANN fCAL® ELISA can therefore be considered as the gold standard in fecal calprotectin testing. Check out our key literature list now
At the ECCO IBD meeting 2016 in Amsterdam the first poster on the performance of the BÜHLMANN Quantum Blue® Infliximab rapid test was presented, including data on high correlations to the Sanquin and Leuven infliximab ELISA tests. The reaction from attendees was enthusiastic, and the application for a high quality quantitative rapid tool to measure
Webinar – Use Basophils as Biomarker for Potency and Efficacy of Drugs in Development with Flow CAST® Inhibitors of PI3K and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays to measure the direct activity of compounds are available in the market
Social Links